Palliative CareECA-PALNCT02750865
Conversational Agents to Improve Quality of Life in Palliative Care
A study testing Embodied Conversational Agent (ECA) in people with Palliative Care, run by Boston Medical Center at 1 site in United States.
Trial summary
In this study the investigators will advance research on the development of easy to use technologies to empower patients. This is a scalable approach that has a significant potential to reduce suffering for palliative care patients and their caregivers. Read more about this study
- Who is it for?
- Ages 21 years and older
- Conditions the study is for
- Palliative Care
- What is being tested?
- Embodied Conversational Agent (ECA)
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 367 participants
- Where
- 1 siteUnited States
- Study dates
- 2 Aug 2017to 24 Oct 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 21 years of age or older
- English speaking
- Able to independently consent to be in the study
- Has adequate corrected vision to be able to use the ECA system (based on a 1-minute ECA functional screener)
- Has adequate hearing to be able to use the ECA system (headphones will be available)
- Has a health care provider who endorses the existence of a potentially life-limiting condition and endorses that it would not be a surprise if the patient died within 12 months (PATIENT-SUBJECTS only)
Who cannot join
- Enrolled in hospice
- Already being followed by the Palliative Care team
- Suicidal or homicidal
- In police custody
- Do not live in the Boston area
- Plan on leaving the Boston area for more than 4 weeks in the next 6 months
- Not able to use the ECA tablet computer
Trial locations and contacts
1 site in 1 country.
About this study
In this study the investigators will advance research on the development of easy to use technologies to empower patients. This is a scalable approach that has a significant potential to reduce suffering for palliative care patients and their caregivers. The investigators will adapt existing tested empathic conversational agents (ECA) for home-based cancer care management and inpatient bedside counseling to provide the following functions:
- medication counseling;
- physical activity promotion;
- symptom management and continual screening for adverse events; and
- alleviation of stress and anxiety
- spiritual needs assessment; and
- advanced care planning.
Read more
Data from the system will be monitored by a health professional, who communicates with members of the patient's care team. In this project, this activity will include facilitating referral for palliative care services.
The investigators will conduct pilot studies both at Boston Medical Center and at Northeastern University that will test system usability (Northeastern University and BMC) as well as interview burden (BMC only).
The investigators will conduct a Randomized Control Trial (RCT) to evaluate the agent technology, comparing usual care (UC) versus usual care plus the agent (UC+ECA) for patients 21 or older, with a life expectancy of < 1 year, from outpatient clinics at Boston Medical Center (BMC). Each subject will be enrolled along with a caregiver surrogate subject. In addition to baseline data collection, there will be monthly phone surveys for six months; intervention subjects will use the system for a six-month period of time. In addition, the investigators will conduct a randomized trial within the intervention group to compare subjects getting functions 1-4 (above) versus subjects getting the augmented intervention with all six functions. The intervention will include a nurse management interface to monitor clinical alerts generated by the system to stimulate interventions by the clinical staff.
Read the detailed description
Pilot Study The pilot study will determine usability of the ECA tablet system. Healthy volunteers will be recruited at Northeastern University, where the system is being developed. Subjects will spend approximately 60 minutes with the tablet system and provide usability feedback. Twelve healthy patient volunteers will be recruited to review the system as well as provide feedback on the relative interview burden (was the interview too long, too invasive, etc). No identifiable data will be collected from pilot study subjects.
Main Study The study will consist of adults with advanced illness (health care provider endorses the existence of a potentially life-limiting condition and endorses that "it would not be a surprise if the patient died within 12 months") who will be randomized to intervention or usual care control groups. Each person with an advanced illness will be enrolled along with a caregiver (i.e., family, friend) who will serve as a surrogate subject. The caregiver will be consented at baseline and interviewed at that point and at the final, 6-month study visit. In addition, if, at any point during their enrollment in the study, the patient-subject becomes unable, or decisionally impaired, to answer interview questions, the caregiver will be asked to answer on behalf of the subject.
The patient can be found to be decisionally impaired in any of 3 ways:
- the patient declares themselves to be unable to answer questions appropriately
- the patient is unable to pass a brief cognitive assessment that will be administered at the beginning of each telephone follow-up (per the Brief Screen for Cognitive Impairment)
- the patient is physically unable to answer questions on the phone (due to, for example, serious health decline or death)
Baseline data will be collected after enrollment and before randomization. Baseline data includes:
- sociodemographic data
- Quality of life as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Palliative Care
- Patient Reported Outcomes Measurement Information System (PROMIS) Mental Health
- Patient Reported Outcomes Measurement Information System (PROMIS) Social Health
- Patient Activation Measure (PAM)
- Patient Medication Adherence Questionnaire (PMAQ)
- Spiritual Needs Assessment for Patients (SNAP)
- Community Healthy Activity Model Program for Seniors (CHAMPS)
- a survey of Advance Care Planning (ACP) communication and preferences
- BSCI (This cognitive assessment is non-exclusionary, but, if the patient scores "0" on the word recall, the designated caregiver/surrogate will be asked to act as the research proxy and answer questions for the patient-subject.)
The investigators will also interview the surrogate subject at baseline regarding their level of caregiver stress with:
- the CarerQol-7D
- the caregiver's level of happiness (CarerQol-VAS)
- self-rated burden (SRB) of care giving After the initial visit, study staff will administer 5 monthly phone surveys (months 1, 2, 3, 4, and 5), where the EORTC QLQ-C15-PAL will be collected. At the beginning of each data collection point study staff will administer the Brief Survey of Cognitive Impairment (BSCI) to determine if the patient is cognitively able to answer questions, and also inquire about unplanned health care utilization (i.e., urgent care, emergency room, hospital observation visits, and hospital admissions).
At the final, 6-month visit, the patient-subject will be interviewed in person, with the surrogate, and the full list of instruments will be administered. In addition, study staff will prepare a summary data report for the patient's clinical team. The report will include obtaining information from the Palliative Care service. The research staff will ask the subject which clinicians of theirs they would like to have receive this information.
Subjects randomized to the intervention will be given a mini-tablet computer configured for the purposes of this study. A research assistant will set up the tablet, enroll subjects into the study database, and train these subjects in the use of the system. Subjects who do not have existing WiFi at home will be provided with a cellular-based router. In such cases, study staff will arrange the WiFi service plan, install the router in the home, and confirm connectivity.
The investigators estimate that in many instances, when a clinician endorses that they would not be surprised if their patient died within 12 months, that this would be the first time they solidified a prognostic outlook in their minds for that patient. Stimulating clinicians to consider their patient's life-expectancy is itself a form of intervention, as this may instigate communication about prognosis with the patient, a re-evaluation of the treatment course, assessment of goals of care, and an improved level of attention to symptoms. The investigators will conduct informational sessions about the study and provide material about palliative care services in each outpatient clinical environment from which subjects will be enrolled. Information will be provided on how clinicians can contact the Palliative Care service to obtain consultation. Clinicians will be encouraged to call for assistance on palliative care needs for intervention subjects, usual care subjects, and non-subjects.
The same measures collected at baseline will also be collected at the final 6-month interview. At the end of study participation the investigators will also prepare a summary data report for the patient's clinical team. The report will include information on obtaining consultation from the Palliative Care service. The research nurse will ask the subject which clinicians of theirs they would like to have receive this information.
- Conditions
- Palliative Care
- Being tested
- Embodied Conversational Agent (ECA)
- Keywords
- biomedical technology, palliative care
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Embodied Conversational Agent (ECA)Behavioural
The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
| Study group | Role | What they receive |
|---|---|---|
| Control Usual Care | No intervention | In this arm the subject receives usual care and just completes the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment. |
| Embodied Conversational Agent (ECA) | Experimental | In this arm the subject is trained how to use a tablet device which they take home for the duration of the study. These subjects complete the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment. Receives: Behavioral: Embodied Conversational Agent (ECA) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of Life of palliative cancer care participants
QOL will be assessed using QLQ-C15-PAL, a 15-scale-item instrument designed to assess the quality of life of participants.
Measured: assessed monthly up to 6 months
Secondary outcomes (14)
Palliative Care services utilization
Rate of receiving palliative care services as evidenced by presence of at least one Palliative Care clinical note in the EMR.
Measured: assessed monthly up to 6 months
Hospital utilization
Data on healthcare utilization will be obtained through EMR review and monthly phone survey of all subjects for six months, or until patient death. The investigators will obtain data on the number of urgent care, emergency room, hospital observation visits, and hospital admissions.
Measured: assessed at 6 months
Cost
Costs will be obtained from the actual observed costs from the annual Medical Expenditure Panel Surveys (MEPS) conducted the Agency for Healthcare Research and Quality (AHRQ), specific to each service type (ED, inpatient stay and outpatient visit) and reason for visit (principal diagnosis). We will also adjust for inflation in costs over time. The primary utilization measure will be the total costs for all ED visits, inpatient stays, and outpatient physician visits. As secondary measures the investigators will examine the cost of different services. As a simple budget impact assessment the investigators will also evaluate the cost of the intervention, specifically, the provision of additional nurse management services.
Measured: assessed at 6 months
Mental health
Mental and Social health will be assessed using the PROMIS Mental Health (including subscales on: depression, anxiety, anger, cognitive function, alcohol use, consequences, and expectancies, psychosocial illness impact, self-efficacy, and smoking,) and PROMIS Social Health (including subscales on: ability to participate in social roles and activities, satisfaction with social roles and activities, social support, social isolation, and companionship) instruments. The NIH PROMIS measures have been subjected to extensive reliability and validity testing.
Measured: assessed at enrollment and at 6 months
Patient activation
Patient Activation will be measured using the Patient Activation Measure (PAM).
Measured: assessed at enrollment and at 6 months
Medication adherence
Medication Adherence will be assessed using the Patient Medication Adherence Questionnaire (PMAQ).
Measured: assessed at enrollment and at 6 months
Symptoms
Symptoms will be assessed using the Edmonton Symptom Assessment Scale-revised (ESAS-r).
Measured: assessed at enrollment and at 6 months
Spiritual Needs
Spiritual Needs will be assessed using the Spiritual Needs Assessment for Patients instrument (SNAP). SNAP includes 23 items in three domains: psychosocial (n=5), spiritual (n=13), and religious (n=5).
Measured: assessed at enrollment and at 6 months
Medical Orders for Life-Sustaining Treatment (MOLST) completion rate
MOLST form completion rate as identified in the Electronic Medical Record
Measured: assessed at enrollment and at 6 months
Advance Care Planning and preferences
ACP communication and preferences will be assessed using a survey that the investigators have used in prior work.
Measured: assessed at enrollment and at 6 months
Physical activity
Physical activity will be assessed using the walking items from the validated CHAMPS questionnaire for older adults. The CHAMPS assesses usual weekly amounts of walking over the previous 4 weeks in minutes per week, and these items have been significantly associated with pedometer steps and were sensitive to change with a prior ECA-based walking promotion intervention for older adults.
Measured: assessed at enrollment and at 6 months
Use of the ECA-PAL system by subjects in the intervention group
Use of the ECA-PAL system will be determined from log files stored in the database, describing the details of all sessions with the patients, including all discussion topics and questions asked.
Measured: assessed at 6 months
Satisfaction with the ECA-PAL system
Satisfaction with the ECA-PAL system will be assessed using attitudinal measures that have been used in the investigators' prior work. These include the 19-item computer program acceptability scale, and the 12-item bonding subscale of the Working Alliance Inventory (WAI).
Measured: assessed at 6 months
Social health
Social health will be assessed using the PROMIS Social Health (including subscales on: ability to participate in social roles and activities, satisfaction with social roles and activities, social support, social isolation, and companionship) instruments.
Measured: assessed at enrollment and at 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Apr 2016 (estimated)
- Study start2 Aug 2017
- Primary completion24 Oct 2022
- Study completion24 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Palliative CareStudies of the same condition, open and under way.
- More trials run by Boston Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 367 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boston Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Northeastern University, Boston University, National Institute of Nursing Research (NINR)
- Responsible party
- Sponsor
- Investigators
- Julien Dedier, MD, Principal investigator, Boston Medical CenterMichael Paasche-Orlow, MD, MPH, Principal investigator, Tufts Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02750865
- Sponsor's protocol ID
- H-34877
- Other IDs
- 1R01NR016131
- Acronym
- ECA-PAL
- Status last verified
- Jul 2023
- First submitted
- 30 Mar 2016
- Last updated
- 13 Jul 2023
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Jul 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Conversational Agents to Improve Quality of Life in Palliative Care
- ClinicalTrials.gov ID
- NCT02750865
- Acronym / sponsor ID
- ECA-PAL / H-34877
- Conditions
- Palliative Care
- Keywords
- biomedical technology, palliative care
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 367 participants (actual)
- Lead sponsor
- Boston Medical CenterUniversity, hospital or other
- Collaborators
- Northeastern University, Boston University, National Institute of Nursing Research (NINR)
- Study start
- 2 Aug 2017 (actual)
- Primary completion
- 24 Oct 2022 (actual)
- Study completion
- 24 Oct 2022 (actual)
- First posted
- 26 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this study the investigators will advance research on the development of easy to use technologies to empower patients. This is a scalable approach that has a significant potential to reduce suffering for palliative care patients and their caregivers. The investigators will adapt existing tested empathic conversational agents (ECA) for home-based cancer care management and inpatient bedside counseling to provide the following functions:
- medication counseling;
- physical activity promotion;
- symptom management and continual screening for adverse events; and
- alleviation of stress and anxiety
- spiritual needs assessment; and
- advanced care planning.
Data from the system will be monitored by a health professional, who communicates with members of the patient's care team. In this project, this activity will include facilitating referral for palliative care services.
The investigators will conduct pilot studies both at Boston Medical Center and at Northeastern University that will test system usability (Northeastern University and BMC) as well as interview burden (BMC only).
The investigators will conduct a Randomized Control Trial (RCT) to evaluate the agent technology, comparing usual care (UC) versus usual care plus the agent (UC+ECA) for patients 21 or older, with a life expectancy of < 1 year, from outpatient clinics at Boston Medical Center (BMC). Each subject will be enrolled along with a caregiver surrogate subject. In addition to baseline data collection, there will be monthly phone surveys for six months; intervention subjects will use the system for a six-month period of time. In addition, the investigators will conduct a randomized trial within the intervention group to compare subjects getting functions 1-4 (above) versus subjects getting the augmented intervention with all six functions. The intervention will include a nurse management interface to monitor clinical alerts generated by the system to stimulate interventions by the clinical staff.
Detailed description
Pilot Study The pilot study will determine usability of the ECA tablet system. Healthy volunteers will be recruited at Northeastern University, where the system is being developed. Subjects will spend approximately 60 minutes with the tablet system and provide usability feedback. Twelve healthy patient volunteers will be recruited to review the system as well as provide feedback on the relative interview burden (was the interview too long, too invasive, etc). No identifiable data will be collected from pilot study subjects.
Main Study The study will consist of adults with advanced illness (health care provider endorses the existence of a potentially life-limiting condition and endorses that "it would not be a surprise if the patient died within 12 months") who will be randomized to intervention or usual care control groups. Each person with an advanced illness will be enrolled along with a caregiver (i.e., family, friend) who will serve as a surrogate subject. The caregiver will be consented at baseline and interviewed at that point and at the final, 6-month study visit. In addition, if, at any point during their enrollment in the study, the patient-subject becomes unable, or decisionally impaired, to answer interview questions, the caregiver will be asked to answer on behalf of the subject.
The patient can be found to be decisionally impaired in any of 3 ways:
- the patient declares themselves to be unable to answer questions appropriately
- the patient is unable to pass a brief cognitive assessment that will be administered at the beginning of each telephone follow-up (per the Brief Screen for Cognitive Impairment)
- the patient is physically unable to answer questions on the phone (due to, for example, serious health decline or death)
Baseline data will be collected after enrollment and before randomization. Baseline data includes:
- sociodemographic data
- Quality of life as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Palliative Care
- Patient Reported Outcomes Measurement Information System (PROMIS) Mental Health
- Patient Reported Outcomes Measurement Information System (PROMIS) Social Health
- Patient Activation Measure (PAM)
- Patient Medication Adherence Questionnaire (PMAQ)
- Spiritual Needs Assessment for Patients (SNAP)
- Community Healthy Activity Model Program for Seniors (CHAMPS)
- a survey of Advance Care Planning (ACP) communication and preferences
- BSCI (This cognitive assessment is non-exclusionary, but, if the patient scores "0" on the word recall, the designated caregiver/surrogate will be asked to act as the research proxy and answer questions for the patient-subject.)
The investigators will also interview the surrogate subject at baseline regarding their level of caregiver stress with:
- the CarerQol-7D
- the caregiver's level of happiness (CarerQol-VAS)
- self-rated burden (SRB) of care giving After the initial visit, study staff will administer 5 monthly phone surveys (months 1, 2, 3, 4, and 5), where the EORTC QLQ-C15-PAL will be collected. At the beginning of each data collection point study staff will administer the Brief Survey of Cognitive Impairment (BSCI) to determine if the patient is cognitively able to answer questions, and also inquire about unplanned health care utilization (i.e., urgent care, emergency room, hospital observation visits, and hospital admissions).
At the final, 6-month visit, the patient-subject will be interviewed in person, with the surrogate, and the full list of instruments will be administered. In addition, study staff will prepare a summary data report for the patient's clinical team. The report will include obtaining information from the Palliative Care service. The research staff will ask the subject which clinicians of theirs they would like to have receive this information.
Subjects randomized to the intervention will be given a mini-tablet computer configured for the purposes of this study. A research assistant will set up the tablet, enroll subjects into the study database, and train these subjects in the use of the system. Subjects who do not have existing WiFi at home will be provided with a cellular-based router. In such cases, study staff will arrange the WiFi service plan, install the router in the home, and confirm connectivity.
The investigators estimate that in many instances, when a clinician endorses that they would not be surprised if their patient died within 12 months, that this would be the first time they solidified a prognostic outlook in their minds for that patient. Stimulating clinicians to consider their patient's life-expectancy is itself a form of intervention, as this may instigate communication about prognosis with the patient, a re-evaluation of the treatment course, assessment of goals of care, and an improved level of attention to symptoms. The investigators will conduct informational sessions about the study and provide material about palliative care services in each outpatient clinical environment from which subjects will be enrolled. Information will be provided on how clinicians can contact the Palliative Care service to obtain consultation. Clinicians will be encouraged to call for assistance on palliative care needs for intervention subjects, usual care subjects, and non-subjects.
The same measures collected at baseline will also be collected at the final 6-month interview. At the end of study participation the investigators will also prepare a summary data report for the patient's clinical team. The report will include information on obtaining consultation from the Palliative Care service. The research nurse will ask the subject which clinicians of theirs they would like to have receive this information.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control Usual Care | No intervention | –In this arm the subject receives usual care and just completes the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment. |
| Embodied Conversational Agent (ECA) | Experimental | Behavioral: Embodied Conversational Agent (ECA)In this arm the subject is trained how to use a tablet device which they take home for the duration of the study. These subjects complete the baseline interview, monthly telephone surveys about their quality of life, and the exit interview at 6 months after enrollment. |
Who may qualify
- Ages
- 21 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- 21 years of age or older
- English speaking
- Able to independently consent to be in the study
- Has adequate corrected vision to be able to use the ECA system (based on a 1-minute ECA functional screener)
- Has adequate hearing to be able to use the ECA system (headphones will be available)
Key exclusion criteria (7 listed)
- Enrolled in hospice
- Already being followed by the Palliative Care team
- Suicidal or homicidal
- In police custody
- Do not live in the Boston area
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Embodied Conversational Agent (ECA)The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning. | Behavioural | Embodied Conversational Agent (ECA) |
Primary outcome
Quality of Life of palliative cancer care participants
Time frame: assessed monthly up to 6 months
QOL will be assessed using QLQ-C15-PAL, a 15-scale-item instrument designed to assess the quality of life of participants.
14 secondary outcomes
Palliative Care services utilization
Time frame: assessed monthly up to 6 months
Hospital utilization
Time frame: assessed at 6 months
Cost
Time frame: assessed at 6 months
Mental health
Time frame: assessed at enrollment and at 6 months
Patient activation
Time frame: assessed at enrollment and at 6 months
Medication adherence
Time frame: assessed at enrollment and at 6 months
Symptoms
Time frame: assessed at enrollment and at 6 months
Spiritual Needs
Time frame: assessed at enrollment and at 6 months
Medical Orders for Life-Sustaining Treatment (MOLST) completion rate
Time frame: assessed at enrollment and at 6 months
Advance Care Planning and preferences
Time frame: assessed at enrollment and at 6 months
Physical activity
Time frame: assessed at enrollment and at 6 months
Use of the ECA-PAL system by subjects in the intervention group
Time frame: assessed at 6 months
Satisfaction with the ECA-PAL system
Time frame: assessed at 6 months
Social health
Time frame: assessed at enrollment and at 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Jul 2023.
- Individual participant dataSharing planned: No
Related trials for Palliative Care
Not yet recruitingObservational study
IN-TALK: Co-producing a Hospice Intimacy Support Toolkit in England
Communication About Intimacy Needs in Hospice and Palliative Care
Not yet recruitingPhase 2
Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
RecruitingPhase 1/2
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
Malignant Solid Neoplasm
Active, not recruiting
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Liver Disease Chronic, End Stage Liver DIsease
Not yet recruiting
Comparing Radiotherapy Dose Strategies for Symptom Relief in Large Solid Tumors
Solid Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Julien Dedier, MD principal investigator
Boston Medical Center
Michael Paasche-Orlow, MD, MPH principal investigator
Tufts Medical Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Embodied Conversational Agent (ECA) in people with Palliative Care, run by Boston Medical Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of Life of palliative cancer care participants (time frame: assessed monthly up to 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2023.